ProCE Banner Activity

Phase I/II Study of Pembrolizumab + Favezelimab, an Anti–LAG-3 mAb, in R/R Classical Hodgkin Lymphoma

Slideset Download
Conference Coverage
Preliminary data suggest that combined treatment with anti–PD-1 and anti–LAG-3 agents provides antitumor activity with a high response rate and durable responses in patients with R/R classical Hodgkin lymphoma naive to anti–PD-1 treatment.

Released: June 15, 2022

Expiration: June 14, 2023

Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

AstraZeneca

BMS

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp

Merck Sharp & Dohme Corp

Novartis Pharmaceuticals Corporation

Seagen

Seagen and Genmab